New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2014
10:00 EDTPAAS, RHT, CVBF, CCMP, SNI, SAIA, MTB, JBHT, GOGO, G, CX, CPST, AHT, ACTOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Actavis (ACT) upgraded to Buy from Neutral at Goldman... Ashford Hospitality (AHT) upgraded to Outperform from Neutral at RW Baird... CEMEX (CX) upgraded to Buy from Neutral at Sterne Agee... Capstone Turbine (CPST) upgraded to Outperform from Market Perform at FBR Capital... Genpact (G) upgraded to Buy from Neutral at Citigroup... Gogo (GOGO) upgraded to Overweight from Equal Weight at Evercore... J.B. Hunt (JBHT) upgraded to Buy from Hold at Wunderlich... M&T Bank (MTB) upgraded to Buy from Neutral at SunTrust... Saia, Inc. (SAIA) upgraded to Buy from Hold at Wunderlich... Scripps Networks (SNI) upgraded at Argus... Cabot Microelectronics (CCMP) upgraded at DA Davidson... CVB Financial (CVBF) upgraded to Outperform from Market Perform at Fig Partners... Red Hat (RHT) upgraded to Outperform from Market Perform at Cowen... Pan American Silver (PAAS) upgraded to Market Perform from Underperform at BMO Capital.
News For ACT;AHT;CPST;CX;G;GOGO;JBHT;MTB;SAIA;SNI;CCMP;CVBF;RHT;PAAS From The Last 14 Days
Check below for free stories on ACT;AHT;CPST;CX;G;GOGO;JBHT;MTB;SAIA;SNI;CCMP;CVBF;RHT;PAAS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 11, 2014
14:36 EDTSNIScripps Networks says trends support FY outlook
Subscribe for More Information
14:28 EDTSNIScripps Networks says interested in OTT options, exploring Internet tv
Scripps Networks Interactive executives are speaking at the the Goldman Sachs Communacopia conference.
11:14 EDTRHTGoogle hires former Red Hat CTO Brian Stevens, GigaOM reports
Subscribe for More Information
09:55 EDTGOGOGogo trades higher on T-Mobile deal, levels to watch
The shares gapped up to $17.52 this morning following news that the company has secured a deal with T-Mobile US (TMUS) to provide free in-flight texting and e-mail for T-Mobile customers. At current price, next resistance is at $18.14. Support is at $17.49.
09:18 EDTGOGOOn The Fly: Pre-market Movers
UP AFTER EARNINGS: lululemon (LULU), up 15%... Sigma Designs (SIGM), up 7%. ALSO HIGHER: JDSU (JDSU), up 13.8% after announcing that it will separate into two publicly traded companies... Wet Seal (WTSL), up 4.5%, upgraded at B. Riley following Q2 earnings results... Gogo (GOGO), up 5% after announcing partnership with T-Mobile (TMUS)... Digital Ally (DGLY), up 8.4% after announcing plans to introduce "bullet camera" option at October police conference. DOWN AFTER EARNINGS: Restoration Hardware (RH), down 5%... Five Below (FIVE), down 5.6%. LOWER: Radio Shack (RSH), down 8% after reporting Q2 losses, stating that it may need to pursue bankruptcy... E2open (EOPN), down 29%, downgraded at Pacific Crest and Northland after the company announced preliminary Q2 earnings results... Twitter (TWTR), down 1% after announcing that it will offer $1.3B in convertible unsecured senior notes... Crocs (CROX), down 2.6% after downgraded at Buckingham... Macy's (M), down 1.3% after downgraded at Sterne Agee.
September 10, 2014
18:33 EDTGOGOOn The Fly: After Hours Movers
Subscribe for More Information
17:52 EDTGOGOGogo higher by over 4% after partnership with T-Mobile announced
16:39 EDTGOGOT-Mobile extends 'Wi-Fi Un-leashed' with Gogo partnership
Subscribe for More Information
16:35 EDTSAIASaia, Inc. appoints Fritz Holzgrefe as CFO
Subscribe for More Information
09:02 EDTACTActavis won't see serious long-term impact from rejection, says Sterne Agee
After the FDA's Cardiovascular and Renal Drugs Advisory Committee voted to recommend against approval of Actavis' New Drug Application for the fixed-dose combination of nebivolol and valsartan for the treatment of hypertension, Sterne Agee does not thinks the vote is very meaningful to the company's longer-term growth and earnings potential. The firm says that removing the product from its revenue outlook causes its 2018 EPS estimate for the company to drop by less than 1%. The firm still thinks the company can easily reach its 2017 EPS target of about $20. Sterne Agee keeps a $272 price target and Buy rating on the shares.
08:56 EDTACTFDA advisors recommend against approval of Actavis' nebivolol/valsartan combo
Actavis last night confirmed that the FDA's Cardiovascular and Renal Drugs Advisory Committee has voted to recommend against approval of Actavis' New Drug Application for the fixed-dose combination of nebivolol and valsartan for the treatment of hypertension. The committee vote was six to four recommending against approval. The committee recommendation is not binding on the FDA, which makes the final decision regarding approval. Actavis expects FDA action on its NDA for the fixed-dose combination of nebivolol and valsartan by the fourth quarter of 2014. Actavis' Senior VP, Global Brands Research and Development, David Nicholson, said, "Although we are disappointed in the Committee's recommendation regarding the fixed-dose combination of nebivolol and valsartan, we remain fully committed to supporting the NDA for this important potential new treatment option for patients with hypertension. We remain confident in the safety and efficacy of the combination of these two widely used and well-tolerated treatments, and we look forward to working with the FDA as it completes its review." Shares of Actavis are down more than 2% in pre-market trading following yesterday's committee recommendation.
07:56 EDTRHTRed Hat October volatility elevated into Q2 and outlook
Subscribe for More Information
07:41 EDTCXBofA/Merrill to hold a conference
European High Yield & Loans Conference 2014 to be held in London, England on September 10.
07:31 EDTSNIGoldman to hold a conference
Subscribe for More Information
07:24 EDTRHTRed Hat coverage assumed with a Neutral at MKM Partners
Subscribe for More Information
07:07 EDTAHTBofA/Merrill to hold a conference
Subscribe for More Information
September 9, 2014
17:06 EDTACTFDA panel votes against Actavis blood pressure pill, Bloomberg says
FDA advisers said that Actavis's experimental pill that combines two existing drugs to lower high blood pressure doesn’t provide a clinically meaningful benefit over the two drugs alone, says Bloomberg. The advisory panel voted 6 to 4 against recommending the treatment, added Bloomberg. Shares of Actavis are trading down almost 1% in after-hours trading. Reference Link
10:38 EDTSNIScripps Networks management to meet with Jefferies
Subscribe for More Information
10:18 EDTACTDollar General listed among 5 largest long positions by Jana Partners
Subscribe for More Information
September 8, 2014
11:05 EDTRHTOptions with increasing implied volatility
Options with increasing implied volatility: NPSP GILD VNET AVNR GTAT YHOO RHT VRTX SDRL COV MYL
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use